Nektar Therapeutics Stock Alpha and Beta Analysis
| NKTR Stock | USD 0.90 0.00 0.000002% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Nektar Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Nektar Therapeutics over a specified time horizon. Remember, high Nektar Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Nektar Therapeutics' market risk premium analysis include:
Beta 1.24 | Alpha (0.02) | Risk 5.78 | Sharpe Ratio (0) | Expected Return (0.01) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Nektar |
Nektar Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Nektar Therapeutics market risk premium is the additional return an investor will receive from holding Nektar Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Nektar Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Nektar Therapeutics' performance over market.| α | -0.02 | β | 1.24 |
Nektar Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Nektar Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Nektar Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Nektar Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Nektar Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Nektar Therapeutics shares will generate the highest return on investment. By understating and applying Nektar Therapeutics stock market price indicators, traders can identify Nektar Therapeutics position entry and exit signals to maximize returns.
Nektar Therapeutics Return and Market Media
The median price of Nektar Therapeutics for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 0.9 with a coefficient of variation of 12.23. The daily time series for the period is distributed with a sample standard deviation of 0.11, arithmetic mean of 0.91, and mean deviation of 0.09. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 19500 shares by Chess Robert of Nektar Therapeutics at 1.2 subject to Rule 16b-3 | 12/16/2024 |
2 | Disposition of 46995 shares by Howard Robin of Nektar Therapeutics at 1.01 subject to Rule 16b-3 | 12/17/2024 |
3 | Disposition of 51115 shares by Jonathan Zalevsky of Nektar Therapeutics at 0.94 subject to Rule 16b-3 | 12/19/2024 |
4 | Disposition of 33402 shares by Mark Wilson of Nektar Therapeutics at 0.9 subject to Rule 16b-3 | 12/23/2024 |
5 | Disposition of 16560 shares by Mark Wilson of Nektar Therapeutics at 0.89 subject to Rule 16b-3 | 12/24/2024 |
6 | Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer | 01/06/2025 |
7 | Nektar Therapeutics Stock Drops Amid Biotech Sector Volatility | 02/07/2025 |
8 | Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer | 02/11/2025 |
9 | Zoetis Tops Q4 Earnings and Revenue Estimates | 02/13/2025 |
10 | Disposition of 23774 shares by Howard Robin of Nektar Therapeutics at 1.01 subject to Rule 16b-3 | 02/19/2025 |
11 | Acquisition by Whitfield Roy A of 20400 shares of Nektar Therapeutics at 3.47 subject to Rule 16b-3 | 02/26/2025 |
12 | Nektar Therapeutics Buy Rating Reiterated at HC Wainwright | 02/28/2025 |
13 | Nektar Therapeutics Q4 Earnings Beat Estimates | 03/12/2025 |
14 | Nektar Therapeutics Earns Market Perform Rating from William Blair | 03/13/2025 |
About Nektar Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Nektar or other stocks. Alpha measures the amount that position in Nektar Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Interest Debt Per Share | 0.86 | 0.75 | 0.87 | 0.82 | Revenue Per Share | 0.49 | 0.47 | 0.43 | 0.41 |
Nektar Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Nektar Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Nektar Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Nektar Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Nektar Therapeutics. Please utilize our Beneish M Score to check the likelihood of Nektar Therapeutics' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Nektar Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Nektar Stock Analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.